Infusystems Holdings, Inc. · AMEX:INFU
Infusystems — InfuSystem Holdings — Investor Presentation (October 2025)
20 slides from Infusystems's investor presentation, Oct 6, 2025
Slide 1: Investor Presentation October 6, 2025
Investor Presentation October 6, 2025 l (NYSE American: INFU) Helping People Live Longer and Healthier Lives
Slide 2: Forward-Looking Statements / Non-GAAP Measures
Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended,
Slide 3: Six Consecutive Years of Record Revenue
Six Consecutive Years of Record Revenue • Revenue CAGR: 12% • Adjusted EBITDA CAGR: 11% 3 81.1 $97.4 $102.4 $109.9 $125.8 $134.9 2019 2020 2021 2022 2023 2024 20 40 60 80 100 120 140 Net Revenues In M ill io ns Investment Highlights 39-Year History | Long-Term Blue Chip Customer Base 2024 Adjusted E
Slide 4: Business Highlights
*Source: Newsweek, World's Best Hospitals 2024 4 Business Highlights A leading provider of medical equipment and patient services powered by a 100K+ device fleet in the U.S. and Canada Nearly four decades of experience, built on existing Oncology therapy model and now rapidly expanding into multiple
Slide 5: Providing Solutions To Manage the Device Throughout the Treatment Cycle
5 Providing Solutions To Manage the Device Throughout the Treatment Cycle Device-Agnostic Services Platform That Improves Health Care Processes and Outcomes Patient • SAFE quality equipment • Home treatment • Last-mile solution • 24-hour patient support • Patient satisfaction surveys Manufacturer •
Slide 6: Sales by Segment
SALES BY SEGMENT Total 2024 Revenue: $134.9 Million $54.5M (40%)$80.4M (60%) Device Solutions Providing equipment, products and services to hospitals, clinics and home infusion providers Patient Services Facilitating outpatient care for patients requiring durable medical equipment Patient Services •
Slide 7: Patient Services and Device Solutions Competitive Advantages
Patient Services • 800+ national payer contracts covering over 96% of U.S. population • Focused and scalable revenue cycle management team • 24/7 clinical hotline • Device agnostic Device Solutions • White Glove Concierge approach • 7 facilities serving U.S. and Canada • More than 200 biomedical tec
Slide 8: Patient Services: Third-Party Payer Model
“The patient is at the center of everything we do.” Patient Services Oncology (Core Business) Is Profitable and Stable Growth Opportunities Are Pain Management and Wound Care Clinical Support/ Case Management Device Logistics Revenue Cycle Management Device Repair & Maintenance 8 Unique High-Service
Slide 9: Device Solutions: Direct Payer Model
Medical Device Sales, Rentals & Leasing Consumable Sales Device Repair & Maintenance Device Solutions Traditional Medical Distribution, Direct Payer Model INFU Is Paid Directly by the Hospital/Clinic/Home Care Provider Trusted Device & Service Provider Inventory & Tracking • Device Solutions (Core B
Slide 10: Managing the Device Throughout the Treatment Cycle
Managing the Device Throughout the Treatment Cycle SOLUTIONS Manufacturer Provider Payer Patient • Distribution • Device support • Improved outcomes • Lower costs • Devices on demand • White Glove services • Third-party payer billing • Access to advanced devices and products • 24/7 patient support C
Slide 11: High-Value Health Care Services Platform
High-Value Health Care Services Platform Specialized Skills We Developed for Oncology Now Being Leveraged in New Therapies and Partnerships 11
Slide 12: InfuSystem's Unique Capabilities Are in High Demand
InfuSystem's Unique Capabilities Are in High Demand February 2021 Acquired and Integrated Two Biomedical Services Companies to Develop and Expand Device Solutions in Acute Care February 2022 Signed Agreement With Solo-Dex Inc. for Proprietary Continuous Peripheral Nerve Block Catheters April 2022 Bi
Slide 13: Quarterly Trends
Quarterly Trends (1) See Appendix A. (2) Includes $0.7M spent in 2024 on replacement of our main enterprise resource planning application ("ERP"), and an estimated $2.5M in 2025. Expected completion in 2026. 13 Net Revenue Quarterly Trend $24.5 $24.8 $26.6 $26.5$26.8 $27.0 $27.3 $28.8 $30.4 $31.7 $3
Slide 14: Annual Financial Performance
Annual Financial Performance 14 $ in M ill io ns $ in M ill io ns Net Revenues $97.4 $102.4 $109.9 $125.8 $134.9 $139.9 2020 2021 2022 2023 2024 TTM 6/30/25 Estimated 2025 $— $20.0 $40.0 $60.0 $80.0 $100.0 $120.0 $140.0 $160.0 Adjusted EBITDA (1) $26.2 $24.0 $20.7 $22.4 $25.3 $29.7 2020 2021 2022 20
Slide 15: Annual Margin Performance
Annual Margin Performance 15 Gross Margin 59.4% 57.2% 55.1% 50.2% 52.2% 54.5% 2020 2021 2022 2023 2024 TTM 6/30/25 —% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% Adjusted EBITDA Margin (1) 26.9% 23.5% 18.9% 17.8% 18.8% 21.2% 2020 2021 2022 2023 20242) TTM 6/30/25(2) Estimated 2025(2) —% 5.0% 10.0% 15.0% 20.
Slide 16: Capital Expenditures & Revenue Growth – TTM
Capital Expenditures & Revenue Growth – TTM 16 Capital Expenditures, Net - TTM (000's) TTM Growth Rate Q 1- 20 19 Q 2- 20 19 Q 3- 20 19 Q 4- 20 19 Q 1- 20 20 Q 2- 20 20 Q 3- 20 20 Q 4- 20 20 Q 1- 20 21 Q 2- 20 21 Q 3- 20 21 Q 4- 20 21 Q 1- 20 22 Q 2- 20 22 Q 3- 20 22 Q 4- 20 22 Q 1- 20 23 Q 2- 20 23
Slide 17: Balance Sheet Highlights
Balance Sheet Highlights 17 (1) July 15, 2025, we amended the 2021 credit agreement. New expiration date July 15, 2030. $ in Millions As of June 30, 2025 Equity $54.5 Total Long-Term Debt 1 $26.3 Net Leverage Ratio 0.86x Debt/Equity Ratio 0.85x Total Available Liquidity $49.1 Cash Provided by Operat
Slide 18: Capital Allocation Priorities
18 Capital Allocation Priorities Investments to Drive Organic Growth Initiatives • Device Solutions – Biomedical Services • Patient Services – SI Health Care Technologies Share Repurchase – Opportunistic • $20M Stock Repurchase Program Renewed May 20, 2024, Expires on June 30, 2026 • Purchased $7.6
Slide 19: Corporate Priorities
Corporate Priorities Maintain Solid Core Business in Oncology and Device Solutions Drive Major Growth Initiatives – Biomedical and Wound Care Continuous Process Enhancements to Boost Net Margins; Sustain Optimal CapEx Efficiency Balance Investment/Growth Initiatives With Improving AEBITDA and Cash F
Slide 20: Appendix A GAAP to Non-GAAP Reconciliation
Appendix A GAAP to NON-GAAP Reconciliation 20 NET INCOME TO ADJUSTED EBITDA: Twelve Months Ended December 31, Six Months Ended June 30, (in thousands) 2021 2022 2023 2024 2024 2025 GAAP net income (loss) $ 1,420 $ 18 $ 872 $ 2,345 $ (395) $ 2,332 Adjustments: Interest expense 1,377 1,402 2,170 1,777
InfuSystem Holdings — Investor Presentation (October 2025) on 6ix